Accentedge Health is actively working on providing automated image-based endpoints to follow up the evolution of solid tumors in cancer patients.

Patient Follow-up


In this framework, we are about to launch our SALMON trial to validate an automatic calculation of the current RECIST scoring (aRECIST, mainly looking at tumor size) and to initiate the work on a next generation optimized RECIST scoring (oRECIST, considering the full tumor phenotype).

We are partners and lead in several European and regional research projects funded by the European Union Horizon 2020 research and innovation program, the Innovative Medicine initiative (IMI) joint undertaking, Eurostars and the Interreg EMR program.
Scroll to Top
Scroll to Top